Trials / Terminated
TerminatedNCT01294397
Effects of Denosumab on the Pharmacokinetics of Etanercept
The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis based on area under the serum concentration-time curve (AUC) and maximum observed serum concentration (Cmax).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept | Administered by subcutaneous injection once a week |
| DRUG | Denosumab | Administered by subcutaneous injection |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2011-02-11
- Last updated
- 2017-06-20
- Results posted
- 2017-06-20
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01294397. Inclusion in this directory is not an endorsement.